S'abonner

21-Hydroxylase–deficient nonclassic adrenal hyperplasia is a progressive disorder: A multicenter study - 05/09/11

Doi : 10.1067/mob.2000.108020 
Carlos Moran, MD, MSca, b, Ricardo Azziz, MD, MPHa, c, Enrico Carmina, MDd, Didier Dewailly, MDe, Franca Fruzzetti, MDf, Lourdes Ibañez, MDg, Eric S. Knochenhauer, MDa, Jose A.M. Marcondes, MDh, Berenice B. Mendonca, MDh, Duarte Pignatelli, MDi, Michel Pugeat, MDj, Vincent Rohmer, MDk, Phyllis W. Speiser, MDl, Selma F. Witchel, MDm
From the Departments of Obstetrics and Gynecologya and Medicine,c The University of Alabama at Birmingham; the Research Unit of Reproductive Medicine, Instituto Mexicano del Seguro Socialb; The University of Palermod; the Centre Hospitalier et Universitaire de Lillee; the University of Pisaf; the Hospital Sant Joan de Deu, University of Barcelonag; the Hospital das Clinicas, São Pauloh; the Faculty of Medicine of Portoi; the Hospices Civils de Lyonj; the Centre Hospitalier Universitaire D’Angersk; the North Shore University Hospitall; and Children’s Hospital of Pittsburgh.m 

Abstract

Objective: Our aim was to determine whether the clinical features of 21-hydroxylase–deficient nonclassic adrenal hyperplasia are correlated with either age at symptom onset or age at presentation, or both, and with the degree of adrenocortical abnormality. Study Design: In a multicenter cohort design 220 women with nonclassic adrenal hyperplasia, with a basal or adrenocorticotropic hormone–stimulated 17-hydroxyprogesterone level >30.3 nmol/L, were studied, either prospectively (n = 39) or retrospectively (n = 181). Patients were stratified by age of presentation into 5 groups: (1) <10 years (n = 25), (2) 10 to 19 years (n = 64), (3) 20 to 29 years (n = 83), (4) 30 to 39 years (n = 30), and (5) 40 to 49 years (n = 16). Two patients >50 years old were excluded from the analysis because of age. Results: Ninety-two percent of patients <10 years old had premature pubarche at presentation, whereas clitoromegaly and acne were each present in only 20% of these younger subjects. With only patients ≥10 years old considered, presenting clinical features included hirsutism (59%), oligomenorrhea (54%), acne (33%), infertility (13%), clitoromegaly (10%), alopecia (8%), primary amenorrhea (4%), and premature pubarche (4%). Among the patients ≥10 years old, the prevalence but not the degree of hirsutism increased significantly with age. Basal levels of 17-hydroxyprogesterone in adolescents were significantly higher than the levels found either in children (<10 years old) or women 40 to 49 years old (P < .01 and P < .03, respectively), although no difference was noted in the stimulated 17-hydroxyprogesterone levels between age groups. The adrenocorticotropic hormone–stimulated levels but not the basal levels of 17-hydroxyprogesterone were significantly higher in patients with clitoromegaly than in women without clitoromegaly. Alternatively, there were no differences in either basal or stimulated 17-hydroxyprogesterone levels between patients with and those without hirsutism, acne, or alopecia. Conclusion: In children <10 years old the most common presenting complaint was premature pubarche, whereas hirsutism and oligomenorrhea were more common in older patients. The prevalence of hirsutism increased with age, suggesting the progressive nature of nonclassic adrenal hyperplasia. Furthermore, the adrenocorticotropic hormone–stimulated levels of 17-hydroxyprogesterone were higher in patients with clitoromegaly, which suggests that the degree of adrenocortical dysfunction in nonclassic adrenal hyperplasia determines, at least in part, the clinical presentation. (Am J Obstet Gynecol 2000;183:1468-74.)

Le texte complet de cet article est disponible en PDF.

 Supported in part by National Institutes of Health grant No. R01-HD29364 (Ricardo Azziz).


© 2000  Academic Press. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 183 - N° 6

P. 1468-1474 - décembre 2000 Retour au numéro
Article précédent Article précédent
  • Gonadotropin-releasing hormone agonist treatment for endometriosis of the rectovaginal septum
  • Luigi Fedele, Stefano Bianchi, Giovanni Zanconato, Luca Tozzi, Ricciarda Raffaelli
| Article suivant Article suivant
  • HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: Onset at ≤28.0 weeks’ gestation
  • Bassam Haddad, John R. Barton, Jeffrey C. Livingston, Rabih Chahine, Baha M. Sibai

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.